The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study

Figures & data

Table 1 Definitions and use of key concepts in major normative institutions

Table 2 Major themes and corresponding qualitative codes

European Medicines Agency. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. Document EMA/CHMP/594085/. 2016.

 Google Scholar

European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. CPMP/EWP/558/95 rev 2. 2011.

 Google Scholar

Food and Drug Administration. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases guidance for industry: U.S. Department of Health and Human Services; 2014. https://www.fda.gov/media/86250/download. Accessed 25 May 2021.

 Google Scholar

Food and Drug Administration. Limited population pathway for antibacterial and antifungal drugs guidance for industry. 2018. https://www.fda.gov/media/113729/download. Accessed 25 May 2021.

 Google Scholar

World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. World Health Organization; 2017.

 Google Scholar

Food and Drug Administration. Guidance for industry expedited programs for serious conditions–drugs and biologics: Food and Drug Administration, U.S. Department of Health and Human Services; 2014. https://www.fda.gov/media/86377/download.

 Google Scholar

European Medicines Agency. Veterinary regulatory 2023. https://www.ema.europa.eu/en/veterinary-regulatory/research-development/scientific-guidelines/novel-therapies. Accessed 5 Mar 2023.

 Google Scholar